Investor Presentaiton

Our North America Generics base business grew at 15% CAGR (FY16 Gr:12%) REVENUES (US $ Mn) +15% STRATEGIC FOCUS 1,168 1,044 921 738 671 Investments in capacity and facilities • Build capabilities for complex dosage forms Augment capacities for Oral Solids and Injectables Deepening go-to-market model Demand generation for non-substitutable products in clinics & hospitals Moving towards branded OTC franchise FY12 FY13 FY14 FY15 FY16 Now ranked #10th among the US generics companies Leading private label OTC player; strong #2 after Perrigo

View entire presentation